您的购物车当前为空
别名 BDTX-189
Tuxobertinib (BDTX-189) 是一种高效可口服的选择性 EGFR 和 HER2变构突变抑制剂,具有抗癌活性。它对 EGFR、HER2、BLK 和 RIPK2 的 KD 值分别为 0.2、0.76、13 和 1.2 nM。


为众多的药物研发团队赋能,
让新药发现更简单!
Tuxobertinib (BDTX-189) 是一种高效可口服的选择性 EGFR 和 HER2变构突变抑制剂,具有抗癌活性。它对 EGFR、HER2、BLK 和 RIPK2 的 KD 值分别为 0.2、0.76、13 和 1.2 nM。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 248 | In stock | |
| 5 mg | ¥ 567 | In stock | |
| 10 mg | ¥ 993 | In stock | |
| 25 mg | ¥ 1,980 | In stock | |
| 50 mg | ¥ 3,390 | In stock | |
| 100 mg | ¥ 4,870 | In stock | |
| 200 mg | ¥ 6,750 | In stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 713 | In stock |
Tuxobertinib 相关产品
| 产品描述 | Tuxobertinib (BDTX-189) is a potent and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations(KDs of 0.2, 0.76, 13 and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively). BDTX-189 exhibits anticancer activity. |
| 靶点活性 | RIPK2:1.2 nM(KD), BLK:13 nM(KD), HER2:0.76 nM(KD), EGFR:0.2 nM(KD) |
| 体内活性 | BDTX-189 (0-100 mg/kg;?p.o.;?daily for 15 dyas) shows dose-dependent tumor growth inhibition and regression in in athymic nude mice bearing HER2 S310F Ba/F3 allograft tumors.?BDTX-189 (1-50 mg/kg.p.o.;?daily for 15 days) shows dose-dependent tumor growth inhibition and regression in athymic nude mice bearing CUTO-14 PDX tumors that express the EGFR mutation EGFR ASV |
| 别名 | BDTX-189 |
| 分子量 | 561.03 |
| 分子式 | C29H29ClN6O4 |
| CAS No. | 2414572-47-5 |
| Smiles | Clc1cc(Nc2ncnc3cc(OCCN4CCOCC4)c(NC(=O)C=C)cc23)ccc1OCc1ccccn1 |
| 密度 | 1.349 g/cm3 (Predicted) |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 41.67 mg/mL (74.27 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
评论内容